MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Incyte Corporation (NASDAQ: INCY)*
Organization & Developments: Incyte
Parents
Incyte Corporation (NASDAQ: INCY)*
Children
*INCB18424, Incyte's compound could be the first treatment approved by the FDA for myelofibrosis, a rare and often fatal disorder that scars bone marrow so it can't manufacture blood cells.
*Sells value-added proprietary protein databases to pharmaceutical and biotechnology companies.
*The company's databases aggregate curated and annoted protein literature with analysis tools to determine protein function from
2011: INCB18424 (Incyte and Novartis) (2011 Predicted Blockbuster)
2013: Incyte PharmaStock Soars As Drug Fights Pancreatic Cancer INCY (2013)
2016: Incyte Plummets After Stopping Trial Of Jakafi In Pancreatic Cancer
2016: Incyte: Another Celgene? - Incyte Corporation (NASDAQ:INCY)
2017: 'ASCO' Boost For These 2 Small Oncology Plays?...Calithera Biosciences (NASDAQ:CALA)
2017: Incyte Teams Up With Dow's Merck To Trounce Roche In Cancer
2018: Body blow for Incyte as Merck-partnered melanoma trial bombs
2018: Incyte Scores Lucrative Deal For Its 3 Pipeline Products_seekingalpha.com
2018: Incyte: This ROTY Contender Is On Sale - Incyte Corporation (NASDAQ:INCY)
2019: CTI BioPharma: Can It Differentiate Itself From Jakafi In MF Patients? - CTI BioPharma Corp. (NASDAQ:CTIC)
2020: Leading Biotech Stock Crashes After Promising Drug Fails Late-Stage Test_www.investors.com
2020: MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte Nasdaq:MGNX
2021: Incyte Q4 2020 Shows Strength; Stock At An Attractive Price
2022: Incyte A Buy As Revenue From Opzelura Ramps_ seekingalpha.com
2022: Incyte Corporation 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2023: Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab_ seekingalpha.com
2024: A word from Incyte: Seven years of excellence as a Science top employe
2024: Incyte Corporation 2023 Q4 - Results - Earnings Call Presentation
2024: Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
2024: Incyte trims cancer drug pipeline in R&D refocus
2024: Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data
2024: Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff
2024: Incyte's SWOT analysis: biotech stock faces patent cliff as pipeline potential grows
2025: Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results
2025: Incyte: Good Company, But Potentially Overvalued Given Patent Cliffs
2025: Incyte: Multiple Drug Launches Bode Well For Future Growth
2025: Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib_seekingalpha.com
2025: Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio
Jumps
*Key People: Incyte
Finance & Acquisitions: Incyte